Epinephrine

證據等級: L5

預測適應症: 4 個

Epinephrine: From Emergency Use (Anaphylaxis/Cardiac Arrest) to Obstructive Lung Disease

One-Sentence Summary

Epinephrine (adrenaline) is a catecholamine classically used for life-threatening emergencies such as anaphylactic shock and cardiac arrest; the evidence pack contains no formally documented original-indication text or Taiwan market license for this drug. The TxGNN model predicts it may also be effective for Obstructive Lung Disease, with a prediction score of 99.71%, supported by 2 completed Phase 3 clinical trials of an epinephrine inhalation aerosol in asthma plus 20 supporting publications. However, a Blocking safety data gap (missing TFDA label/warnings) currently prevents this candidate from entering formal safety pre-assessment.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (no original-indication or TFDA license text on file)
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.71%
Evidence Level	L1
US Market Status	Not Marketed (未上市)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action data is not available in this evidence pack (data gap DG002, severity High). Based on well-established pharmacology, epinephrine is an endogenous catecholamine and non-selective adrenergic agonist acting on α1, α2, β1, and β2 receptors. Its β2-agonist activity relaxes bronchial smooth muscle (bronchodilation), which is the pharmacological basis for its historical use as an emergency bronchodilator in acute bronchospasm and anaphylaxis.

This β2-mediated bronchodilation mechanism directly explains the model’s prediction for obstructive lung disease — a category spanning asthma, COPD exacerbation, and bronchiolitis. In fact, this is less a novel repurposing hypothesis than a mechanistically confirmed, historically precedented use: an epinephrine inhalation aerosol (E004, later marketed OTC as Primatene Mist HFA) completed multiple Phase 3 clinical trials specifically in pediatric and adult asthma, and racemic epinephrine nebulization has long been used (with debated efficacy) in bronchiolitis. This convergence of mechanism, historical use, and completed Phase 3 trial data reinforces the plausibility of the model’s high prediction score (99.71%).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01460511	Phase 3	Completed	70	Multi-center RCT of epinephrine inhalation aerosol (E004) vs. placebo HFA-MDI in children 4-11y with asthma; evaluated bronchodilator efficacy and safety
NCT01737905	Phase 3	Completed	28	Randomized, double-blind, placebo-controlled crossover single-dose study of epinephrine (E004) in pediatric asthma
NCT01025648	Phase 1/2	Terminated	9	Dose-ranging RCT comparing Armstrong’s Epinephrine HFA-MDI (E004) vs. placebo and active control (Epinephrine CFC-MDI) in adult asthma
NCT01255709	Phase 2	Completed	24	Crossover PK study using deuterium-labeled epinephrine to distinguish exogenous drug from endogenous epinephrine in healthy volunteers
NCT01143051	Phase 1/2	Completed	24	PK and safety study of epinephrine inhalation aerosol HFA-MDI (E004) under augmented dose conditions
NCT00116584	Phase 3	Completed	72	RCT of heliox-driven racemic epinephrine nebulization vs. air-oxygen driven nebulization in moderate-severe pediatric bronchiolitis
NCT01834820	Phase 4	Completed	120	RCT evaluating epinephrine, dexamethasone, and hypertonic saline in children with bronchiolitis
NCT03614273	NA	Completed	60	RCT comparing nebulized hypertonic saline (3%) vs. nebulized adrenaline (epinephrine) for bronchiolitis
NCT01300325	Phase 4	Completed	136	RCT of nebulized hypertonic saline plus epinephrine vs. normal saline plus epinephrine in hospitalized infants with bronchiolitis
NCT01216553	Phase 4	Unknown	135	Case-control study of home oxygen therapy vs. standard nebulized therapy (including 0.1% nebulized epinephrine) in bronchiolitis with hypoxia

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21678340	2011	Systematic Review	Cochrane Database Syst Rev	Cochrane review on epinephrine bronchodilator use for bronchiolitis; effectiveness remains uncertain despite widespread use
14974006	2004	Systematic Review	Cochrane Database Syst Rev	Earlier Cochrane review finding bronchodilators (including epinephrine) produce modest short-term benefit in mild-moderate bronchiolitis
4606289	1974	Clinical Study	Clin Pharmacol Ther	Comparative study of bronchodilator effects of terbutaline and epinephrine in patients with obstructive lung disease (abstract not provided)
4551435	1972	Clinical Study	Annals of Allergy	Nebulized bronchodilators, including epinephrine, in obstructive lung disease (Part II; abstract not provided)
30488718	2019	Review	Expert Rev Respir Med	Reviews the role of racemic epinephrine, corticosteroids, hypertonic saline, and HFOT in pediatric bronchiolitis (2009-2018 literature)
30856157	2019	Review	Medical Letter Drugs Ther	Reports the return of OTC epinephrine inhaler (Primatene Mist) for asthma bronchospasm relief
19135584	2009	Review	Pediatr Clin North Am	Reviews acute bronchiolitis and croup treatment, including nebulized adrenaline for symptomatic relief
21486501	2011	Review	BMJ Clinical Evidence	Overview of bronchiolitis as the most common lower respiratory infection in infants
19450362	2007	Review	BMJ Clinical Evidence	Earlier overview of bronchiolitis epidemiology and management
6417212	1983	Review	J Allergy Clin Immunol	Classic review characterizing childhood asthma as an obstructive pulmonary airway disease

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available at this data cutoff (TFDA label not yet obtained; DDI query returned no results).

Conclusion and Next Steps

Decision: Hold

Rationale: Clinical evidence is strong (L1: ≥2 completed Phase 3 RCTs of epinephrine inhalation aerosol in asthma, plus longstanding bronchodilator precedent), but the Blocking data gap — absence of TFDA-approved label warnings/contraindications — prevents the mandatory S1 safety pre-assessment, so the candidate must Hold until that gap is resolved.

To proceed, the following is needed:

TFDA package insert (PDF) retrieval and parsing to obtain warnings/contraindications (DG001, Blocking)
DrugBank API query for complete mechanism-of-action data (DG002, High)
A working drug-drug interaction (DDI) data source (current query: not_found)
Confirmation of Taiwan market/license status directly against TFDA records (currently: not marketed, 0 licenses on file)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.